Abstract
Tenascins represent a family of extracellular matrix glycoproteins with distinctive expression patterns. Here we have analyzed the most recently described member, tenascin-W, in breast cancer. Mammary tumors isolated from transgenic mice expressing hormone-induced oncogenes reveal tenascin-W in the stroma around lesions with a high likelihood of metastasis. The presence of tenascin-W was correlated with the expression of its putative receptor, α8 integrin. HC11 cells derived from normal mammary epithelium do not express α8 integrin and fail to cross tenascin-W-coated filters. However, 4T1 mammary carcinoma cells do express α8 integrin and their migration is stimulated by tenascin-W. The expression of tenascin-W is induced by BMP-2 but not by TGF-β1, though the latter is a potent inducer of tenascin-C. The expression of tenascin-W is dependent on p38MAPK and JNK signaling pathways. Since preinflammatory cytokines also act through p38MAPK and JNK signaling pathways, the possible role of TNF-α in tenascin-W expression was also examined. TNF-α induced the expression of both tenascin-W and tenascin-C, and this induction was p38MAPK- and cyclooxygenase-dependent. Our results show that tenascin-W may be a useful diagnostic marker for breast malignancies, and that the induction of tenascin-W in the tumor stroma may contribute to the invasive behavior of tumor cells.
Similar content being viewed by others
References
Adams M, Jones JL, Walker RA, Pringle JH and Bell SC . (2002). Cancer Res., 62, 3289–3297.
Andres AC, Schonenberger CA, Groner B, Hennighausen L, LeMeur M and Gerlinger P . (1987). Proc. Natl. Acad. Sci. USA, 84, 1299–1303.
Andres AC, van der Valk MA, Schonenberger CA, Fluckiger F, LeMeur M, Gerlinger P and Groner B . (1988). Genes Dev., 2, 1486–1495.
Chen J, Baskerville C, Han Q, Pan ZK and Huang S . (2001). J. Biol. Chem., 276, 47901–47905.
Chiquet-Ehrismann R . (2004). Int. J. Biochem. Cell Biol., 36, 986–990.
Chiquet-Ehrismann R and Chiquet M . (2003). J. Pathol., 200, 488–499.
Chiquet-Ehrismann R and Tucker RP . (2004). Int. J. Biochem. Cell Biol., 36, 1085–1089.
Clement JH, Sanger J and Hoffken K . (1999). Int. J. Cancer, 80, 250–256.
Fischer D, Tucker RP, Chiquet-Ehrismann R and Adams JC . (1997). Mol. Biol. Cell, 8, 2055–2075.
Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S, Kawai S, Faucheu C, Huet L, Baron R and Roman-Roman S . (2001). Bone, 28, 491–498.
Geffrotin C, Horak V, Crechet F, Tricaud Y, Lethias C, Vincent-Naulleau S and Vielh P . (2000). Biochim. Biophys. Acta, 1524, 196–202.
Goepel C, Buchmann J, Schultka R and Koelbl H . (2000). Gynecol. Oncol., 79, 372–378.
Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G and Caverzasio J . (2003). J. Bone Mineral Res., 18, 2060–2068.
Hasegawa K, Yoshida T, Matsumoto K, Katsuta K, Waga S and Sakakura T . (1997). Acta Neuropathol., 93, 431–437.
Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A and Orend G . (2001). Cancer Res., 61, 8586–8594.
Hynes NE, Taverna D, Harwerth IM, Ciardiello F, Salomon DS, Yamamoto T and Groner B . (1990). Mol. Cell Biol., 10, 4027–4034.
Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ and Pavlidis N . (2002). Eur. J. Cancer, 38, 2362–2370.
Jones FS and Jones PL . (2000). Dev. Dyn., 218, 235–259.
Kaya H, Hucumenoglu S, Bozkurt SU, Ekicioglu G and Kotiloglu E . (2002). Eur. J. Gynaecol. Oncol., 23, 261–263.
Latijnhouwers MA, Pfundt R, de Jong GJ and Schalwijk J . (1998). Matrix Biol., 17, 305–316.
Lemonnier J, Ghayor C, Guicheux J and Caverzasio J . (2004). J. Biol. Chem., 279, 259–264.
Li F, Strange R, Friis RR, Djonov V, Altermatt HJ, Saurer S, Niemann H and Andres AC . (1994). Int. J. Cancer, 59, 560–568.
Liu LX, Jiang HC, Liu ZH, Zhou J, Zhang WH, Zhu AL, Wang XQ and Wu M . (2002). World J. Gastroenterol., 8, 631–637.
Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y and Sakakura T . (1987). Proc. Natl. Acad. Sci. USA, 84, 4621–4625.
Malik ST, Naylor MS, East N, Oliff A and Balkwill FR . (1990). Eur. J. Cancer, 26, 1031–1034.
Michalaki V, Syrigos K, Charles P and Waxman J . (2004). Br. J. Cancer, 90, 2312–2316.
Munarini N, Jager R, Abderhalden S, Zuercher G, Rohrbach V, Loercher S, Pfanner-Meyer B, Andres AC and Ziemiecki A . (2002). J. Cell Sci., 115, 25–37.
Neidhardt J, Fehr S, Kutsche M, Lohler J and Schachner M . (2003). Mol. Cell Neurosci., 23, 193–209.
Nikolova Z, Djonov V, Zuercher G, Andres AC and Ziemiecki A . (1998). J. Cell Sci., 111, 2741–2751.
Ocvirk J, Stabuc B, Rudolf Z, Galvani V and Curin-Serbec V . (2000). Melanoma Res., 10, 253–258.
Pouliot F, Blais A and Labrie C . (2003). Cancer Res., 63, 277–281.
Qin Z, Kruger-Krasagakes S, Kunzendorf U, Hock H, Diamantstein T and Blankenstein T . (1993). J. Exp. Med., 178, 355–360.
Salh B, Marotta A, Wagey R, Sayed M and Pelech S . (2002). Int. J. Cancer, 98, 148–154.
Scherberich A, Tucker RP, Samandari E, Brown-Luedi M, Martin D and Chiquet-Ehrismann R . (2004). J. Cell Sci., 17, 571–581.
Schnapp LM, Hatch N, Ramos DM, Klimanskaya IV, Sheppard D and Pytela R . (1998). J. Biol. Chem., 270, 23196–23202.
Schoenenberger CA, Andres AC, Groner B, van der Valk M, LeMeur M and Gerlinger P . (1988). EMBO J., 7, 169–175.
Schultz RM . (2003). Prog. Drug Res., 60, 59–92.
Schwalbe M, Sanger J, Eggers R, Naumann A, Schmidt A, Hoffken K and Clement JH . (2003). Int. J. Oncol., 23, 89–95.
Tsunoda T, Inada H, Kalembeyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y and Yoshida T . (2003). Am. J. Pathol., 162, 1857–1867.
Vinals F, Lopez-Rovira T, Rosa JL and Ventura F . (2002). FEBS Lett., 510, 99–104.
Weber P, Montag D, Schachner M and Bernhardt RR . (1998). J. Neurobiol., 35, 1–16.
Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE and Yu D . (2001). Cancer Res., 61, 1727–1732.
Zweers MC, van Vlijmen-Willems IM, van Kuppevelt TH, Mecham RP, Steijlen PM, Bristow J and Schalkwijk J . (2004). J. Invest. Dermatol., 122, 885–891.
Acknowledgements
This research was supported by grants from the Novartis Research Foundation and the Krebsliga beider Basel (A Scherberich) and the National Science Foundation (0235711; RP Tucker).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scherberich, A., Tucker, R., Degen, M. et al. Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro. Oncogene 24, 1525–1532 (2005). https://doi.org/10.1038/sj.onc.1208342
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208342
- Springer Nature Limited
Keywords
This article is cited by
-
The extracellular matrix in tumor progression and metastasis
Clinical & Experimental Metastasis (2019)
-
Mapping tenascin-C interaction with toll-like receptor 4 reveals a new subset of endogenous inflammatory triggers
Nature Communications (2017)
-
The arthritis severity locus Cia5a regulates the expression of inflammatory mediators including Syk pathway genes and proteases in pristane-induced arthritis
BMC Genomics (2012)
-
Expression of tenascin-C and its isoforms in the breast
Cancer and Metastasis Reviews (2010)